Effect of Atorvastatin on Platelet Thromboxane A2 Synthesis in Aspirin-Treated Patients With Acute Myocardial Infarction

American Journal of Cardiology

Volumn 104, Issue 12, 2009, Pages 1618-1623

  Santos, M Teresa ^a   Fuset, M Paz ^a   Ruano, Miguel ^a   Moscardó, Antonio ^a   Valles, Juana ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; HEPARIN; NITRIC ACID DERIVATIVE; THROMBOXANE A2;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG MECHANISM; FATTY ACID SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; HYPOTHESIS; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; SEROTONIN RELEASE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; BLOOD PLATELETS; DRUG THERAPY, COMBINATION; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PYRROLES; THROMBOXANE A2; TREATMENT OUTCOME;

EID: 70749093467     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.07.039     Document Type: Article

References (22)

1. 2 synthesis by aspirin is associated with myonecrosis in patients with ST-Segment elevation myocardial infarction. Am J Cardiol 99 (2007) 19-25
2. Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., Zeiher A., Chaitman B.R., Leslie S., and Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
3. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., and Skene A.M. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
4. Patti G., Pasceri V., Colonna G., Miglionico M., Fischetti D., Sardella G., Montinaro A., and Di Sciascio G. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 49 (2007) 1272-1278
5. Hoffmann R., Haager P., Suliman H., Christott P., Radke P., Blindt R., and Kelm M. Effect of statin therapy before Q-wave myocardial infarction on myocardial perfusion. Am J Cardiol 101 (2008) 139-143
6. Lenderink T., Boersma E., Gitt A.K., Zeymer U., Wallentin L., Van de Werf F., Hasdai D., Behar S., and Simoons M.L. Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than non-users: a report from the first Euro Heart Survey on acute coronary syndromes. Eur Heart J 27 (2006) 1799-1804
7. Nagashima M., Koyanagi R., Kasanuki H., Hagiwara N., Yamaguchi J., Atsuchi N., Honda T., Haze K., Sumiyoshi T., Urashima M., and Ogawa H. Effect of early statin treatment at standard doses on long-term clinical outcomes in patients with acute myocardial infarction (the Heart Institute of Japan, Department of Cardiology Statin Evaluation Program). Am J Cardiol 99 (2007) 1523-1528
8. Liao J.K. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 96 (2005) 24F-33F
9. Schror K., Lobel P., and Steinhagen-Thiessen E. Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia. Eicosanoids 2 (1989) 39-45
10. Davi G., Averna M., Catalano I., Barbagallo C., Ganci A., Notarbartolo A., Ciabattoni G., and Patrono C. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation 85 (1992) 1792-1798
11. Notarbartolo A., Davi G., Averna M., Barbagallo C.M., Ganci A., Giammarresi C., Laplaca F.P., and Patrono C. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 15 (1995) 247-251
12. Eikelboom J.W., Hankey G.J., Thom J., Bhatt D.L., Steg P.G., Montalescot G., Johnston S.C., Steinhubl S.R., Mak K.-H., Easton J.D., Hamm C., Hu T., Fox K.A.A., and Topol E.J. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation 118 (2008) 1705-1712
13. Santos M.T., Valles J., Marcus A.J., Safier L.B., Broekman M.J., Islam N., Ullman H.L., Eiroa A.M., and Aznar J. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. J Clin Invest 87 (1991) 571-580
14. Valles J., Santos M.T., Aznar J., Martinez M., Moscardo A., Pinon M., Broekman M.J., and Marcus A.J. Platelet-erythrocyte interactions enhance alpha(IIb)beta(3) integrin receptor activation and P-selectin expression during platelet recruitment: down-regulation by aspirin ex vivo. Blood 99 (2002) 3978-3984
15. 2 and prothrombotic effects of erythrocytes are important determinants of aspirin resistance in patients with vascular disease. Thromb Haemostas 6 (2008) 615-621
16. Valles J., Santos M.T., Aznar J., Marcus A.J., Martinez-Sales V., Portoles M., Broekman M.J., and Safier L.B. Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, ADP release, and recruitment. Blood 78 (1991) 154-162
17. Valles J., Santos M.T., Aznar J., Osa A., Lago A., Cosin J., Sanchez E., Broekman M.J., and Marcus A.J. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 97 (1998) 350-355
18. Santos M.T., Moscardó A., Vallés J., Martinez M., Piñón M., Aznar J., Broekman M.J., and Marcus A.J. Participation of tyrosine phosphorylation in cytoskeletal reorganization, alphaIIbbeta3 integrin receptor activation and aspirin-insensitive mechanisms of thrombin-stimulated human platelets. Circulation 102 (2000) 1924-1930
19. Osamah H., Mira R., Sorina S., Shlomo K., and Michael A. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. Br J Clin Pharmacol 44 (1997) 77-83
20. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 344 (1994) 1383-1389
21. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J., and West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
22. 2 on admission are associated with no-reflow after primary percutaneous coronary intervention. Eur Heart J 29 (2008) 1843-1850